Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium reported Q1 2026 net revenue of $193.5 million, up 9% year-over-year, driven by a 36% increase in JORNAY PM revenue to $38.9 million. The company is on track to close the $650 million acquisition of AZSTARYS in Q2 2026, which is expected to be immediately accretive and extend revenues into the late 2030s.
Key figures
- Eps
- 0.4
- Revenue
- $193.5 million
- Guidance
- FY2026 Product Revenues $805-$825 million; JORNAY PM Revenue $190-$200 million; Adjusted EBITDA $455-$475 million
- Revenue Yoy
- 9%
- Adjusted ebitda
- $103.9 million
- Belbuca revenue
- $52.6 million
- Cash equivalents
- $421.8 million
- Jornay pm revenue
- $38.9 million
- Xtampza er revenue
- $50.8 million
- Cash from operations
- $57.1 million
- Pain portfolio revenue
- $154.6 million
- Nucynta franchise revenue
- $47.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.